| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
|
Ann Oncol
|
2007
|
5.68
|
|
2
|
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
|
Ann Oncol
|
2012
|
5.32
|
|
3
|
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
|
J Clin Oncol
|
2000
|
4.25
|
|
4
|
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
|
Lancet
|
1998
|
4.16
|
|
5
|
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
|
J Clin Oncol
|
2001
|
3.21
|
|
6
|
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
|
Ann Oncol
|
2002
|
2.87
|
|
7
|
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
|
Ann Oncol
|
2005
|
2.84
|
|
8
|
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
|
J Clin Oncol
|
2000
|
2.77
|
|
9
|
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
|
Ann Oncol
|
2002
|
2.60
|
|
10
|
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).
|
Ann Oncol
|
2013
|
2.53
|
|
11
|
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor).
|
Oncogene
|
1999
|
2.10
|
|
12
|
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.
|
Ann Oncol
|
2009
|
1.93
|
|
13
|
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).
|
Ann Oncol
|
2012
|
1.84
|
|
14
|
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer.
|
Eur J Cancer
|
2004
|
1.70
|
|
15
|
Primary liver tumour of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour?
|
Liver
|
1998
|
1.67
|
|
16
|
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2012
|
1.67
|
|
17
|
Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole.
|
Rev Infect Dis
|
1981
|
1.58
|
|
18
|
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
|
Eur J Cancer
|
2005
|
1.58
|
|
19
|
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
|
Eur J Cancer
|
2011
|
1.57
|
|
20
|
Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying.
|
Gut
|
1998
|
1.54
|
|
21
|
Modelling the polypeptide backbone with 'spare parts' from known protein structures.
|
Protein Eng
|
1989
|
1.54
|
|
22
|
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication.
|
Endoscopy
|
2012
|
1.44
|
|
23
|
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
|
Ann Oncol
|
2007
|
1.44
|
|
24
|
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
|
Ann Oncol
|
2007
|
1.44
|
|
25
|
Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination.
|
Gastroenterology
|
1992
|
1.33
|
|
26
|
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).
|
Ann Oncol
|
2009
|
1.29
|
|
27
|
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations.
|
Ann Oncol
|
2008
|
1.29
|
|
28
|
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
|
Ann Oncol
|
2003
|
1.26
|
|
29
|
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.
|
Ann Oncol
|
2009
|
1.26
|
|
30
|
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.
|
Br J Cancer
|
2009
|
1.25
|
|
31
|
Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquids.
|
J Nucl Med
|
1990
|
1.22
|
|
32
|
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET).
|
Eur J Cancer
|
2001
|
1.19
|
|
33
|
Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
|
J Clin Oncol
|
1999
|
1.19
|
|
34
|
Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
|
Eur J Nucl Med Mol Imaging
|
2002
|
1.17
|
|
35
|
Patient acceptance for CT colonography: what is the real issue?
|
Eur Radiol
|
2002
|
1.15
|
|
36
|
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
|
Br J Cancer
|
2007
|
1.15
|
|
37
|
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
|
J Clin Oncol
|
1998
|
1.14
|
|
38
|
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
|
Eur J Cancer
|
1995
|
1.12
|
|
39
|
Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy.
|
Ann Surg
|
2000
|
1.11
|
|
40
|
Current treatments and future perspectives in colorectal and gastric cancer.
|
Ann Oncol
|
2003
|
1.11
|
|
41
|
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
|
Ann Oncol
|
2011
|
1.11
|
|
42
|
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
|
Ann Oncol
|
2013
|
1.06
|
|
43
|
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
|
Ann Oncol
|
2014
|
1.03
|
|
44
|
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
|
Ann Oncol
|
2007
|
1.02
|
|
45
|
Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009.
|
Ann Oncol
|
2010
|
1.01
|
|
46
|
Pancreatic cancer treatment and research: an international expert panel discussion.
|
Ann Oncol
|
2011
|
1.01
|
|
47
|
The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
|
J Thorac Cardiovasc Surg
|
2000
|
1.00
|
|
48
|
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
|
J Clin Oncol
|
1996
|
1.00
|
|
49
|
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.
|
Ann Oncol
|
2005
|
1.00
|
|
50
|
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
|
Br J Cancer
|
2013
|
0.99
|
|
51
|
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
|
Ann Oncol
|
2015
|
0.97
|
|
52
|
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
|
Ann Oncol
|
2004
|
0.97
|
|
53
|
Size quantification of liver metastases in patients undergoing cancer treatment: reproducibility of one-, two-, and three-dimensional measurements determined with spiral CT.
|
Radiology
|
1997
|
0.96
|
|
54
|
Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour).
|
Br J Cancer
|
2001
|
0.94
|
|
55
|
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
|
Invest New Drugs
|
2006
|
0.94
|
|
56
|
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.
|
Ann Oncol
|
2002
|
0.94
|
|
57
|
The role of chemotherapy in biliary tract carcinoma.
|
HPB (Oxford)
|
2008
|
0.93
|
|
58
|
EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients.
|
Cancer Treat Rev
|
2009
|
0.93
|
|
59
|
Optimizing the use of irinotecan in colorectal cancer.
|
Oncologist
|
2001
|
0.92
|
|
60
|
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.
|
Ann Oncol
|
2002
|
0.91
|
|
61
|
Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases.
|
Eur J Surg Oncol
|
2001
|
0.90
|
|
62
|
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
|
Ann Oncol
|
2012
|
0.90
|
|
63
|
New directions in the treatment of colorectal cancer: a look to the future.
|
Eur J Cancer
|
2000
|
0.89
|
|
64
|
HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?
|
Ann Oncol
|
2012
|
0.89
|
|
65
|
Effect of motilin on gastric emptying in patients with diabetic gastroparesis.
|
Gastroenterology
|
1992
|
0.89
|
|
66
|
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.
|
Br J Cancer
|
2012
|
0.88
|
|
67
|
Effects of preoperative chemoradiotherapy on postsurgical morbidity and mortality in cT3-4 +/- cM1lymph cancer of the oesophagus and gastro-oesophageal junction.
|
Eur J Cardiothorac Surg
|
2003
|
0.87
|
|
68
|
Transcatheter embolization of hepatic arteriovenous fistulas in Rendu-Osler-Weber disease: a case report and review of the literature.
|
Eur Radiol
|
1999
|
0.86
|
|
69
|
Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
|
Eur J Cancer
|
1999
|
0.85
|
|
70
|
Surgery for gastric remnant carcinoma following Billroth II gastrectomy.
|
Eur J Surg Oncol
|
1997
|
0.83
|
|
71
|
Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration.
|
J Hepatol
|
1990
|
0.83
|
|
72
|
Visualization and characterization of gastric contractions using a radionuclide technique.
|
Am J Physiol
|
1990
|
0.83
|
|
73
|
Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working.
|
Acta Gastroenterol Belg
|
2012
|
0.83
|
|
74
|
Quality assurance in colonoscopy for colorectal cancer diagnosis.
|
Eur J Surg Oncol
|
2010
|
0.83
|
|
75
|
Effect of proximal vagotomy and Roux-en-Y diversion on gastric emptying kinetics in asymptomatic patients.
|
Clin Nucl Med
|
1990
|
0.82
|
|
76
|
Toxicity of irinotecan in patients with colorectal cancer.
|
N Engl J Med
|
2001
|
0.82
|
|
77
|
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.
|
Ann Oncol
|
2013
|
0.81
|
|
78
|
Reporting on the results of cancer treatment in patients with metastatic liver disease: proposal of symmetric size-dependent CT-criteria for response.
|
Ann Oncol
|
1996
|
0.81
|
|
79
|
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
|
Br J Cancer
|
2013
|
0.81
|
|
80
|
Carcinoid heart disease--a hidden complication of neuroendocrine tumours.
|
Acta Gastroenterol Belg
|
2009
|
0.81
|
|
81
|
Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?
|
Acta Gastroenterol Belg
|
2009
|
0.79
|
|
82
|
The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
|
Acta Gastroenterol Belg
|
2009
|
0.78
|
|
83
|
Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.
|
Acta Clin Belg
|
2008
|
0.78
|
|
84
|
The EORTC Gastrointestinal Tract Cancer Group: 40 years of research contributing to improved GI cancer management.
|
Eur J Cancer
|
2002
|
0.78
|
|
85
|
Germline mutations of the hMLH1 and hMSH2 mismatch repair genes in Belgian hereditary nonpolyposis colon cancer (HNPCC) patients.
|
Fam Cancer
|
2006
|
0.78
|
|
86
|
Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer.
|
Q J Nucl Med Mol Imaging
|
2004
|
0.78
|
|
87
|
Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration.
|
Eur J Cardiothorac Surg
|
1997
|
0.78
|
|
88
|
Persisting anorectal dysfunction after rectal cancer surgery.
|
Colorectal Dis
|
2013
|
0.77
|
|
89
|
Chemo-radiotherapy versus radiotherapy alone in the pre-operative treatment of resectable rectal cancer.
|
Eur J Surg Oncol
|
2005
|
0.77
|
|
90
|
Quality of care indicators in rectal cancer.
|
Acta Gastroenterol Belg
|
2011
|
0.77
|
|
91
|
The molecular basis of colorectal cancer.
|
Acta Gastroenterol Belg
|
2001
|
0.77
|
|
92
|
Different gastritis features are linked to different gastric neoplasms.
|
Gastroenterol Clin Biol
|
1999
|
0.77
|
|
93
|
Yield of routine imaging after curative colorectal cancer treatment.
|
Acta Chir Belg
|
2008
|
0.76
|
|
94
|
Psychological implications of living with familial adenomatous polyposis.
|
Acta Gastroenterol Belg
|
2011
|
0.76
|
|
95
|
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
|
Colorectal Dis
|
2003
|
0.76
|
|
96
|
Familial adenomatous polyposis: clinical presentation, detection and surveillance.
|
Acta Gastroenterol Belg
|
2011
|
0.76
|
|
97
|
Different surgical strategies in the treatment of familial adenomatous polyposis: what's the role of the ileal pouch-anal anastomosis?
|
Acta Gastroenterol Belg
|
2011
|
0.76
|
|
98
|
Computed tomographic colonography.
|
Acta Gastroenterol Belg
|
2005
|
0.75
|
|
99
|
Malignant degeneration of esophageal squamous papilloma associated with the human papillomavirus.
|
Gastroenterology
|
1992
|
0.75
|
|
100
|
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
|
Br J Cancer
|
2006
|
0.75
|
|
101
|
Report on the Belgian consensus meeting on colorectal cancer screening.
|
Acta Gastroenterol Belg
|
2005
|
0.75
|
|
102
|
Quality assurance and recommendations for quality assessment of screening colonoscopy in Belgium.
|
Acta Gastroenterol Belg
|
2009
|
0.75
|
|
103
|
Compassionate use of Gemzar in advanced pancreatic cancer: a Belgian experience.
|
Acta Gastroenterol Belg
|
2002
|
0.75
|
|
104
|
Multiple brain abscesses caused by Torulopsis glabrata in an immunocompromised patient.
|
Mykosen
|
1986
|
0.75
|
|
105
|
Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
|
Anticancer Drugs
|
1999
|
0.75
|
|
106
|
Clinical characteristics and management of insulin-producing neuroendocrine carcinomas.
|
Acta Gastroenterol Belg
|
2016
|
0.75
|
|
107
|
Screening applications for MRI in the detection of upper abdominal disease: comparative study of non-contrast-enhanced single-shot MRI and contrast-enhanced helical CT.
|
Eur Radiol
|
1999
|
0.75
|
|
108
|
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
|
Oncology
|
2004
|
0.75
|
|
109
|
Intestinal metaplasia in gastric malignancy: a comparison between carcinoma and lymphoma.
|
Eur J Gastroenterol Hepatol
|
1998
|
0.75
|
|
110
|
FAPA--familial adenomatous polyposis association the Belgian Polyposis Registry.
|
Acta Gastroenterol Belg
|
2011
|
0.75
|
|
111
|
Lymphocytic meningitis: a review of the literature.
|
Acta Clin Belg
|
1987
|
0.75
|
|
112
|
Malignant involvement of the knee synovium in a patient with metastastic oesophageal adenocarcinoma.
|
Acta Clin Belg
|
2010
|
0.75
|
|
113
|
Treatment of a metastasis of a rectal carcinoma in the greater trochanter with the AO/ASIF Proximal Femoral Nail. A case report.
|
Acta Chir Belg
|
2004
|
0.75
|
|
114
|
Radioimmunoguided surgery for colorectal carcinoma.
|
Hepatogastroenterology
|
1999
|
0.75
|
|
115
|
A new imaging technique for colorectal cancer: positron emission tomography.
|
Semin Oncol
|
2000
|
0.75
|
|
116
|
Cell kinetic measurements: principles, guidelines for treatment?
|
Hepatogastroenterology
|
1999
|
0.75
|
|
117
|
Curative management of adenocarcinoma of the oesophagus and oesogastric junction--current recommendations of the Belgian Working Group.
|
Acta Gastroenterol Belg
|
2001
|
0.75
|
|
118
|
Follow-up of colon cancer: detection of liver metastases: benefit and periodicity.
|
Acta Gastroenterol Belg
|
1998
|
0.75
|
|
119
|
The potential role of targeted therapies in the management of neuroendocrine tumours.
|
Acta Gastroenterol Belg
|
2009
|
0.75
|
|
120
|
Diagnostic pitfalls in digestive neuroendocrine tumours.
|
Acta Gastroenterol Belg
|
2009
|
0.75
|